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Abstract
The natural history of the LV systolic function (LV-SF) and functional capacity of survivors of heart transplantation (Htx) has not been
defined. Some investigators suggest that SF may be different in recipients with different pre-transplant aetiologies: ischaemic or dilated,
idiopathic disease. Routine transthoracic echocardiograms (TTE) were performed during a 1-year follow-up in 48 Htx recipients (total 864
examinations; mean 18ypatient). Patients were divided into two groups based on pre-transplant diagnosis: ischaemic (CAD-CMP: ns13, age
54"1.7 years, 23% females) and idiopathic dilated cardiomyopathy (ID-CMP: ns35, age 51"2.3 years, 26% females). Patients with valvular
and toxic aetiology were excluded. All patients underwent left ventriculography (VENT) 12–15 months after Htx. The majority of 1-year
survivors of Htx maintained normal LV-SF: mean LVEF 65"4% by echocardiography and 68"3% by ventriculography, but in the ID-CMP group
LVEF was significantly higher: 67"4% vs. 62"4% (TTE) and 77"4% vs. 60"4% (VENT), without significant differences in functional capacity
(NYHA). 82.9% of ID-CMP patients had LVEF )65% vs. 39% in CAD-CMP. The incidence of acute cellular rejection, freedom from cardiac
vasculopathy, renal failure, diabetes, hypertension and pre-transplant alloantibody level was similar. Our study shows a strong correlation
between pre-transplant heart disease and the systolic function of the cardiac allograft at 1-year follow-up.
 2008 Published by European Association for Cardio-Thoracic Surgery. All rights reserved.
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1. Introduction
Heart transplantation (Htx) has proven to be an effective
treatment option for patients with end-stage heart disease
w1x. However, even in the best situations, survival is limited,
and variable with different pathologies. The two most
common aetiologies leading to Htx, dilated and ischaemic
cardiomyopathy, have a significantly different prognosis,
far more unfavourable in the latter. The reasons for this
different behaviour are largely unknown.
Besides routine transmyocardial biopsy, echocardiographic
assessment of the left ventricular ejection fraction (LVEF)
is now becoming a well established method of short and
long-time evaluation of graft condition w2x. In clinically
well Htx recipients, LVEF is usually normal. However, the
natural history of systolic function in survivors has not been
defined. Furthermore, little is known about potential dif-
ferences in recipients with different pre-transplant aetiol-
ogies and its potential impact on survival.
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In this work, we analyse a group of Htx patients, to
determine the evolution of the systolic left ventricular
function and attempt to correlate it with pre-transplanta-
tion aetiology.
2. Material and methods
Between November 2003 and December 2007, a total of
111 adult patients underwent primary orthotopic heart
transplantation and constitute our total experience with
this procedure.
We observed prospectively 48 consecutive Htx survivors
during the first year of follow-up following transplantation
performed in 2005 and 2006. The indication for Htx during
the study period was ischaemic cardiomyopathy in 13 (CAD-
CMP group, age 54"3.7 years, 23% females), idiopathic or
familiar dilated cardiomyopathy in 35 (ID-CMP group, age
51"4.3 years, 26% females). Four patients who had valvu-
lar, toxic or hypertrophic cardiomyopathy were excluded
from this study.
All patients were in NYHA functional class III or IV at the
time of transplantation. Other pre-operative clinical data
are presented in Table 1. CAD-CMP patients had a higher
incidence of hypertension. Otherwise, there were no
differences between the two groups.
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Age (years) 54.0"3.7 51.1"4.3 0.04
Females 23% 25% 0.82
NYHA III 68% 72% 0.93
NYHA IV 32% 28% 0.93
Creatinine )1.4 15% 17% 0.78
Diabetes 23% 14% 0.76
Hypertension 54% 17% 0.029
Previous sternotomy 15% 0 0.14
Donors
Age (years) 23.4"4.8 21.9"6.1 0.42
% Females 15% 13% 0.78
Recipient Mydonor F 31% 31% 0.73
Cause of deathytrauma 61% 68% 0.91
Cause of deathystroke 39% 32% 0.91
Table 2
Patients’ clinical data at 1-year follow-up
CAD-CMP ID-CMP P-value
Rejection G3A 3 (23%) 6 (17%) 0.69
CMVq 9 (69%) 28 (80%) 0.46
Renal failure 1 (8%) 4 (11%) 1.0
Diabetes 3 (23%) 2 (6%) 0.11
Hypertension 10 (78%) 19 (54%) 0.2
BMI -25 2 (15%) 20 (57%) 0.021
BMIs25–29.9 9 (70%) 13 (37%) 0.059
BMI G30 2 (15%) 2 (6%) 0.29
Demographic data of donors were identical in both groups.
As far as possible, size mismatches between donors and
recipients were limited to a maximum of 20% of body
weight, and there were no differences between the two
groups of patients in this respect. All patients received ABO
compatible allografts. None of the donors were known to
have significant co-morbid disease. Local and distant pro-
curement were 39% and 61%, respectively, identical for
both groups. Transthoracic echocardiographic examinations
(TTE) were performed in all donors prior to transplantation
and none had a structural abnormality.
Total (bicaval) transplantation was performed in all
patients. Reperfusion was initiated immediately after the
pulmonary veins and aortic anastomoses were completed.
There were no significant differences between the two
groups with regards to graft ischaemic time (mean 82 vs.
84 min) and extra-corporeal circulation time (101 vs.
98 min), and length of ventilation (5.0 vs. 4.5 h) and of
hospital stay (13 vs. 12 days).
All recipients received immunosuppression, with cyclo-
sporine or tacrolymus, mycophenolate mofetil and corti-
costeroids, following generally accepted protocols. All
patients were followed at a dedicated outpatient clinic by
the transplantation group of physicians.
2.1. Echocardiographic data
All patients were assessed by two-dimensional trans-tho-
racic echocardiography (TTE) using a standard institutional
protocol (all admissions for endomyocardial biopsy and
intermediate outpatient visits), between 7 days and
12 months after Htx. Eight hundred and sixty-four routine
TTE (mean, 18 per patient) were performed during a
1-year follow-up in the 48 Htx recipients. Left ventricular
ejection fraction was calculated by the biplane Simpson’s
method w3x.
2.2. Haemodynamic data and graft rejection
Endomyocardial biopsies were performed according to
classical, internationally accepted protocols. Full right and
left catheterisation with ventriculography and coronary
angiography were performed one year after Htx procedure
using standard techniques. An average of 13 biopsies per
patient were performed during the follow-up period. Biopsy
specimens were graded for acute cellular rejection using
the revised International Society of Heart and Lung Trans-
plantation grading system w4x.
2.3. Data analysis
The data were collected prospectively in a dedicated data
base (spreadsheet) and analysed at the end of follow-up.
Means and standard deviations were automatically
calculated.
Normally distributed continuous variables are represented
as mean"standard deviation (S.D.) or as the percentage
of the sample. The x -test and Fisher’s exact test were2
used to determine differences in patient characteristics
and events. Continuous variables (EF) were compared by
the Student t-test.
A P-value -0.05 was considered significant for all tests.
3. Results
Operative and in-hospital mortality for the 106 patients
was 2.8% (3 patients) and late mortality was 8%. Three-
year actuarial survival was 86%.
The clinical data at 1-year are shown in Table 2. The
incidence and frequency of acute cellular rejection was
similar in both groups w3 in the CAD-CMP group (23%) and 6
in the ID-CMP group (17%)x. All rejection episodes observed
in the study group were subclinical (G grade 2R of the
ISHLT classification). No relationship was found between
echo findings and rejection episodes. Freedom from cardiac
vasculopathy (no case identified by coronary angiography
in either group), incidence of CMV positive serology and
renal failure were also similar.
At 1 year, diabetes, hypertension and obesity rates were
significantly higher in the CAD-CMP group.
The values of LVEF measured during the follow-up by TTE
are represented in Fig. 1 and those measured by left
ventriculography (VENT) at 1 year are shown in Fig. 2. The
majority of 1-year survivors of Htx maintained normal left
ventricular ejection fraction: mean LVEF 65"4% by TTE
and 68"3% by VENT, but in the ID-CMP group the LVEF was
higher: 67"2% vs. 62"2% by TTE in the CAD-CMP, and
77"2% vs. 60"2% by VENT (P-0.01).
Twenty-nine patients (83%) in the ID-CMP group had LVEF
G65% vs. only five (39%) in the CAD-CMP group (Fig. 3). At
the end of the follow-up period, none of the patients with
ID-CMP had LVEF F40%, vs. 3 (23%) of the CAD-CMP group
(Fig. 4).
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Fig. 1. LVEF by transthoracic echocardiography (TTE).
Fig. 2. LVEF by ventriculography (VENT).
Fig. 4. Percentage of patients with LVEFF40%.
Fig. 3. Percentage of patients with LVEFG65% (VENT).
There were no significant differences in functional capac-
ity (NYHA) between the two groups. All patients but 3 are
in NYHA class I.
4. Discussion
According to the most recent data of the Registry of the
International Society of Heart and Lung Transplantation,
the current survival rates for cardiac transplantation are
around 80% at 1 year, 65% at 5 years and 50% at 10 years
w5x. The majority of long-term survivors of Htx maintain
normal left ventricular ejection fraction w6x. In the expe-
rience of Lietz et al., left ventricular dysfunction (defined
as LVEF F40%) developed in 15.8% recipients at 10 years
and increased the risk of cardiac death (ORs2.7) w7x.
However, survival varies widely between different groups
of aetiology. It is well known that it is lower in patients
with ischaemic cardiomyopathy, especially when compared
to dilated cardiomyopathy. This is especially true for one-
year survivors w5x. But the time-frame and causes for these
differences remain largely unknown. The evolution of sys-
tolic ventricular function may reveal some clues about this
different behaviour. New-onset or evolution of ischaemic
heart disease in transplanted patients with known risk
factors for this pathology is likely to occur, but this is
usually a relatively chronic and delayed process and diag-
nosis of the disease by common methods does not occur
until late.
The impact of a history of ischaemic heart disease on the
long-term survival of Htx patients has been demonstrated
by some authors. Shiba et al. w8x compared two groups of
Htx patients: one group consisted of patients who survived
-10 years and the other of patients who survived
)10 years. A history of ischaemic heart disease was found
to have a negative impact on survival. A similar conclusion
was derived by Stoica and co-workers w9x.
Routine evaluation of heart transplant recipients is usually
based on right heart catheterisation with biopsy, but the
invasive nature of these diagnostic procedures have led to
the search for less invasive, also less expensive, methods.
Non-invasive assessment of cardiac structure and function
is typically done by 2-D trans-thoracic echocardiography.
Other authors have demonstrated the usefulness of TTE in
some subgroups of patients as an additional method to
monitor for rejection in a non-invasive and frequent manner
w10x. Advances in echocardiographic techniques indicate a
potential important role for the reliable detection of rejec-
tion by this modality in the future. Appreciation of typical
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alterations from ‘normal’ may allow to identify clinically
significant changes and to avoid unnecessary invasive pro-
cedures based on misinterpretation of these differences
w2x.
Our findings demonstrate a moderate agreement between
left heart catheterisation and echocardiography in the
assessment of LVEF. Although echocardiography is very load
sensitive, the relative homogeneity of the measurements
in an average of 18 echocardiograms in each patient per-
mits a reasonable degree of confidence in the results. The
slightly and almost uniformly lower LVEF obtained by echo-
cardiography, as compared to catheterisation data, most
likely reflects limitations resulting from geometric assump-
tions, as well as inadequate visualisation of the left ven-
tricular outflow tract and potential foreshortening of the
left ventricular apex, as previously demonstrated by
Chuang et al. using two- and three-dimensional echocardio-
graphy and magnetic resonance imaging w11x.
A surprising finding of our study was the strong correlation
between pre-transplant heart disease and the evolution of
the systolic function of the cardiac allograft after only
1 year of follow-up, in the absence of significant differenc-
es in functional capacity between the two groups.
We have observed a decrease of the LVEF in patients of
the ischaemic cardiomyopathy group, significantly different
from that observed in the dilated cardiomyopathy group,
which remained relatively constant during this first year of
follow-up, in the absence of differences between the two
groups with regards to preoperative patient characteristics
and of those of the donors and transplanted organs. Fur-
thermore, a significant percentage of patients in the
ischaemic group had significant LV dysfunction (EFF40%).
Nonetheless, some authors have found that low EF after
HT, especially with later onset, is not associated with poor
survival and is not related to haemodynamically significant
rejection w12x. Others have found a better sensitivity of
the myocardial performance index that combines both
systolic and diastolic performances, which seems to be a
useful adjunct in the follow-up of cardiac transplant
patients.
The leading risk factors for left ventricular dysfunction
(cardiac allograft vasculopathy, renal failure, acute rejec-
tion and age -40 years) were not different in both groups
of our study. Hypertension was three times more common
in the ischaemic patients before surgery (suggesting the
probability of a raised systemic vascular resistance). This
may be one of the causes for the deteriorating LV function
in ischaemic patients, but it does not invalidate the con-
clusions of the study. On the other hand, there are sugges-
tions that severe cardiac dysfunction in heart recipients is
associated with neurocognitive dysfunction, which is evi-
dent among patients with cardiac diseases associated with
poor health behaviours (i.e. coronary artery disease) when
compared to individuals with congenital, viral or unknown
(idiopathic) aetiology w13x. A generalised vascular factor is,
probably, the common factor.
After infection and rejection, graft vasculopathy is one of
the leading causes of death, in the first year after Htx and
the first leading cause in the following years w3x. Obesity
and dyslipidemia act as predictors for the development of
graft vasculopathy and, therefore, as risk factors for sur-
vival w14x. In our patients, the pre-transplant incidence of
overweight or obesity, hypertension and diabetes appeared
higher, although not reaching statistical significance, in the
ischaemic cardiomyopathy group and this became even
more notorious in the postoperative period. This should
constitute a motivation for tighter control of these risk
factors.
The gold standard in the diagnosis of cardiac allograft
vasculopathy is coronary angiography and intra-vascular
ultra-sonography (IVUS). But recent evidence demonstrates
that CAV can be identified using information on donor age,
wall motion score at rest and AT-III staining late after HTx.
Hence, coronary angiography may eventually become lim-
ited to patients with a high probability score and may not
be necessary routinely for surveillance of CAV w15x.
In conclusion, we have identified a very early deteriora-
tion of systolic function in patients with pre-transplant
diagnosis of ischaemic cardiomyopathy. To our knowledge,
this has not been reported before. Identification of patients
with faster deterioration of the LVEF may help treat these
patients, especially by implementing measures to reduce
risk factors for the development of graft vasculopathy.
Further work is required to correlate these echocardio-
graphic changes with vascular changes.
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Conference discussion
Dr. A. Poncelet (Brussels, Belgium): I thought that there was a couple of
3A rejection during the first year of follow-up, and we know that it
(rejection) can be correlated to an impaired left ventricular function. So, I
would just ask you: did the echo data that are included in your analysis
exclude the time period within which it could have been related to rejection?
Dr. Antunes: Well, rejection Grade 3A, none clinical, just by biopsy, was
observed in about 20% of the patients. These results are at 1-year for
ventriculography. So, at least from that time of the study, it was no
coincidence. But if it was, it was one of the cases.
The results of echocardiography were the mean for those 18 observations
during the year because we thought that it was better. But they were
compared to the immediate postoperative, 7-day postoperative, ejection
fraction which was within normal range in all patients.
We all know that survival is worse in ischemic patients and what we notice
is that these changes can already be confirmed by echocardiography, at one
year. There is no change in the patient’s functional class. It’s probably too
early. But this change is in the ejection fraction, probably reflecting the
late survival. And what we want to do now is to make sure that we have
identified a group of patients who have this small ejection fraction and
perhaps we can change our immunosuppression protocol or give these
patients medical treatment, vasodilators and beta blockers, to prevent an
accelerated deterioration of the systolic function.
Dr. D. Tixier (Paris, France): I’d like to know what is your hypothesis
about this difference between the cardiomyopathy group and the cardiac
ischemic group?
Dr. Antunes: As you will see in the manuscript, none of the coronary
angiographies was abnormal, at least by macroscopic evidence. But we feel
that maybe echocardiography can help us at least to detect early systolic
dysfunction which can predict deterioration at a later stage. I don’t have
any other hypothesis for this. It’s just that it probably confirms that ischemic
cardiomyopathy is an entity with worse prognosis. Our experience is only of
three years. We’re learning from our own experience as well as from that
of others, but perhaps we should single out our patients with ischemic
cardiomyopathy and treat them differently from day 1, because some
modifications are evident by 1-year post transplant.
If you have any explanation, I would welcome it. Do you treat patients,
your patients, ischemic and dilated cardiomyopathy, differently?
Dr. Tixier: No, we don’t, but perhaps we should. I don’t know. I don’t
have any explanation for that.
Dr. G. Laufer (Innsbruck, Austria): It’s well known for patients with
general atherosclerotic and vascular disease that there is endothelial dys-
function. And after transplantation, I would submit that the endothelial
dysfunction risk factor causing this endothelial dysfunction are still persist-
ent. A lot of people are smoking after transplantation, hypercholesterolemia,
diabetes and all these kind of risk factors are persistent, so could you
speculate that maybe it’s a microvascular problem that is reflected as
depressed LV function in some of these patients?
Dr. Antunes: Naturally in the manuscript we discuss all those possibilities.
The only reason for presentation of these data is the fact that we could not
find a similar report indicating that echocardiography, which is increasingly
used as a non-invasive method, could detect these changes in the ischemic
group so early after transplantation. And we’re using the same modern
protocols of immunosuppression as everybody else uses. All our patients, in
fact, are on MMF and we have not withdrawn steroids in any of them and
most are on cyclosporin, although we have used tacrolimus in some, but
maybe ischemic patients should be treated differently.
Dr. G. Dellgren (Stockholm, Sweden): To me it seems hard, anyway, to
believe that it’s the etiology of the disease that gives this outcome. Have
you looked into the, I mean, for instance, the donor hearts? I mean, it’s not
only the coronary angiograms pre-transplant but the echos on the pre-
transplant. And for instance, is there a difference in how they have been
managed postoperatively in terms of afterload reduction? And that could
also give different results in these.
Dr. Antunes: We did routine echocardiograms in all our donors. Our system
permits that. And in any analysis that we made of the characteristics of the
donor hearts, we couldn’t find any differences. Of course, it’s only 48
patients. We may increase this group for a bigger analysis and see if we can
find something. But we have so far not sensed any difference in the whole
group of over 100 patients.
We were puzzled by the fact that 1 year after surgery we saw such evident
changes in one group as compared to the other group, which prompted us
to query whether we should not be treating them from the beginning
differently.
In terms of cardio-active agents, we’re only using diltiazem in every single
patient as a routine. But these ischemic patients were preoperative smokers
hypertensive patients more frequently. They were postoperatively hyperten-
sive also a little bit more frequently, although there were no statistical
differences. I don’t know if doing a different treatment will influence the
outcome, but certainly we should investigate and try to do this differently.
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